&Partners’s ResMed RMD Stock Holding History

&Partners’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5.96M	Buy	26,582 +4,455	+20%	+$1.11M	0.03%	475
2025 Q4	$5.33M	Buy	22,127 +15,710	+245%	+$4.02M	0.03%	470
2025 Q3	$5.37M	Buy	6,417 +513	+9%	+$140K	0.03%	398
2025 Q2	$1.52M	Buy	5,904 +2,503	+74%	+$597K	0.01%	786
2025 Q1	$753K	Buy	3,401 +1,313	+63%	+$307K	0.01%	938
2024 Q4	$484K	Buy	2,088 +1,121	+116%	+$270K	0.01%	1087
2024 Q3	$233K	Buy	+967	New	+$216K	﹤0.01%	1230

Other funds holding RMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

&Partners's RMD Position: Q1 2026 in Review

&Partners increased its ResMed (RMD) stake by 20% in Q1 2026, buying an estimated $1.11M and bringing the position to 26,582 shares worth $5.96M. The position accounts for 0.03% of the portfolio, ranked #475.

&Partners first reported a position in RMD in Q3 2024 and has held it in 7 quarters since. 938 funds tracked by Wall St. Rank hold RMD as of Q1 2026.

&Partners held 26,582 shares of ResMed worth $5.96M as of Q1 2026.
&Partners bought 4,455 ResMed shares in Q1 2026, an estimated $1.11M.
ResMed made up 0.03% of &Partners's portfolio in Q1 2026, its #475 holding.
&Partners first reported a position in ResMed in Q3 2024 and has held it in 7 quarters since.
938 funds tracked by Wall St. Rank held ResMed as of Q1 2026.

Based on &Partners's 13F filing for Q1 2026, filed 15 May 2026.